Try one of the below options to narrow down your search.
 |
Documents may be browsed by date, eg; Today, May, 2013.
Past years can be browsed too, eg; 2012, 2011, 2010, 2009 ...
Documents can be searched within a period by browsing to the date and then using the search form; or by direct links, eg; Media releases from 2013
Document tags (shown below the document date, eg; Schedule, SAForms, consultation ...) have highest priority when search results are ranked, followed by title, abstract and full text of document.
Parentheses and the keywords and, or and not have special meaning in search terms. And is implicit and can be omitted; or must be specified.
Remember to group or statements with parentheses if they are beside and statements.
Search examples
- consultation
- Search for consultations
- media and not antibiotics
- Search for media related documents that don't mention antibiotics.
- (media or consultation) and vaccines
- Search for media releases and consultation documents mentioning vaccinations.
Search term: Q
2012
PHARMAC documents that matched your search:
Candersartan Brand Switch
(2 pages, 418 KB)
2012/05/18
“Will the tablets or pack look different? Yes. Because Candestar is made by a different”
Will the tablets or pack look different? Yes. Because Candestar is made by a different supplier, the Candestar tablets will look a bit different from the brand you are currently taking, but they will still have the same medicine and…
Metoprolol Succinate Brand Switch
(2 pages, 640 KB)
2012/05/18
“Will the tablets or pack look different? Yes. Because Metoprolol-AFT CR is made by”
Will the tablets or pack look different? Yes. Because Metoprolol-AFT CR is made by a different supplier, the Metoprolol-AFT CR tablets will look a bit different from the brand you are currently taking, but they will still have the same…
Information sheet for Exceptional Circumstances
(6 pages, 127 KB)
2012/01/17
“Q: A: What are the requirements for funding for my patients under Exceptional Circumstances? There”
INFORMATION SHEET FOR COMMUNITY, HOSPITAL AND CANCER EXCEPTIONAL CIRCUMSTANCES Q: A: What are the requirements for funding for my patients under Exceptional Circumstances? There are three ways to obtain Exceptional Circumstances approval: Community Exceptional Circumstances Hospital Exceptional…
Schedule Update - effective 1 February 2012
(41 pages, 590 KB)
2012/01/18
“Q 200 tab 200 mg to be delisted 1 February 2012. 250 Q 200 56 REMIFENTANIL”
Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 February 2012 Cumulative for January and February 2012 Section H cumulative for December 2011, January and February 2012 Contents Summary of PHARMAC decisions effective 1 February 2012 …. 3 Subsidy…
Exceptional Circumstances information sheet
(6 pages, 115 KB)
2012/03/01
“Q: A: What are the requirements for continued funding for my patients under Exceptional Circumstances”
INFORMATION SHEET FOR COMMUNITY, HOSPITAL AND CANCER EXCEPTIONAL CIRCUMSTANCES Beginning 1 March 2012, PHARMAC’s Exceptional Circumstances (EC) Policy was replaced by the Named Patient Pharmaceutical Assessment (NPPA) Policy. Patients approved for EC funding prior to 1 March 2012 will continue…
Schedule Update - effective 1 June 2012
(45 pages, 1056 KB)
2012/05/17
“Q Q 200 ................................................................ 33 Quinine sulphate ................................................ 33 R Raloxifene hydrochloride .................................... 25 Ranbaxy-Cefaclor............................................... 40 Recombinant”
Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 June 2012 Cumulative for May and June 2012 Section H cumulative for April, May and June 2012 Only annually for hard copy Schedule and Updates $55 www. schedule. co.nz today…
Schedule Update - effective 1 March 2012
(62 pages, 895 KB)
2012/02/16
“Q Q 200 .................................................... 45, 48, 51 Quinine sulphate .................................... 45, 48, 51 R Ranbaxy Cefaclor ............................................... 33 Remifentanil”
Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 March 2012 Cumulative for January, February and March 2012 Section H cumulative for December 2011, January, February and March 2012 Contents Summary of PHARMAC decisions effective 1 March 2012 …..…
2012-02 PTAC Minutes
(26 pages, 168 KB)
2012/04/20
“Q max and long term safety in the open label phase. The Committee noted that”
PTAC meeting held 16 & 17 February 2012 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and PTAC Subcommittees 2008. Note: • • that this…
Version 2.0 of the Prescription for Pharmacoeconomic Analysis
(78 pages, 585 KB)
2012/06/18
“Q statistic in an individual trial or the Cochran Q statistic across the pooled result”
PHARMAC Authors and Reviewers Rachel Grocott Health Economist / Team Leader Rico Schoeler Acting Manager, Analysis and Assessment Virginia Priest Health Economist / Analyst Cameron Hall Health Economist / Analyst Scott Metcalfe Chief Advisor Population Medicine Matthew Brougham Acting Chief…
Schedule Update - effective 1 April 2012
(59 pages, 747 KB)
2012/03/16
“Q Q 200 ................................................................ 52 Quinine sulphate ................................................ 52 R Ranbaxy-Cefaclor......................................... 39, 54 Rizamelt....................................................... 23, 31 57 Index”
Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 April 2012 Cumulative for January, February, March and April 2012 Section H for April 2012 Contents Summary of PHARMAC decisions effective 1 April 2012 …. 3 Ethinyloestradiol with levonorgestrel ……
